208 related articles for article (PubMed ID: 15878063)
21. Incidence, risk factors and outcomes of cataract surgery after plaque brachytherapy for posterior uveal melanoma.
Gill VT; Stålhammar G
Heliyon; 2024 Jan; 10(1):e23447. PubMed ID: 38173489
[TBL] [Abstract][Full Text] [Related]
22. Radiobiological doses, tumor, and treatment features influence on outcomes after epiescleral brachytherapy. A 20-year retrospective analysis from a single-institution: part II.
Miguel D; de Frutos-Baraja JM; López-Lara F; Saornil MA; García-Álvarez C; Alonso P; Diezhandino P
J Contemp Brachytherapy; 2018 Aug; 10(4):347-359. PubMed ID: 30237818
[TBL] [Abstract][Full Text] [Related]
23. Anatomical and Functional Outcomes after Endoresection and Adjuvant Ruthenium Brachytherapy for Uveal Melanoma: A Single-Center Experience.
Mazzini C; Vicini G; Di Leo L; Massi D; Rizzo S; Giansanti F
Life (Basel); 2023 Mar; 13(4):. PubMed ID: 37109431
[TBL] [Abstract][Full Text] [Related]
24. Visual Outcomes after Proton Therapy for Recurrent Uveal Melanoma.
Steinkerchner MS; Hartley CD; Lane AM; Wu F; Gragoudas ES; Kim IK
Ophthalmol Retina; 2024 Jun; ():. PubMed ID: 38878898
[TBL] [Abstract][Full Text] [Related]
25. Predicting Visual Acuity Deterioration and Radiation-Induced Toxicities after Brachytherapy for Choroidal Melanomas.
Espensen CA; Appelt AL; Fog LS; Gothelf AB; Thariat J; Kiilgaard JF
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31390850
[TBL] [Abstract][Full Text] [Related]
26. The prognostic implication of visual acuity at the time of uveal melanoma diagnosis.
Asplund E; Fili M; Pansell T; Brautaset R; Nilsson M; Stålhammar G
Eye (Lond); 2023 Aug; 37(11):2204-2211. PubMed ID: 36434284
[TBL] [Abstract][Full Text] [Related]
27. Predictors of Local Recurrence and Progression-Free Survival in Iodine-125 Brachytherapy-Treated Uveal Melanomas: A Modern Institutional Study.
Gurayah AA; Peters VA; Jin W; Kalahasty K; Kwon D; Zhao W; Patel NV; Markoe AM; Correa ZM; Studenski MT; Harbour JW; Samuels SE
Ocul Oncol Pathol; 2022 Nov; 8(3):175-180. PubMed ID: 37431398
[TBL] [Abstract][Full Text] [Related]
28. Ocular oncology service during the COVID-19 outbreak: uveal melanoma characteristics presenting in 2019 compared to 2020.
Mc Glacken-Byrne A; Murtagh P; O'Neill V; Horgan N
Ir J Med Sci; 2023 Dec; 192(6):2607-2611. PubMed ID: 36805408
[TBL] [Abstract][Full Text] [Related]
29. Comparative Single Vesicle Analysis of Aqueous Humor Extracellular Vesicles before and after Radiation in Uveal Melanoma Eyes.
Sirivolu S; Peng CC; Neviani P; Xu BY; Berry JL; Xu L
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892225
[TBL] [Abstract][Full Text] [Related]
30. Globe Salvage and Vision Preservation by Neoadjuvant Darovasertib and Crizotinib in Uveal Melanoma.
Hiong A; O'Day R; Fog LS; McKay D; McKenzie J; Ameratunga M; Joshua AM; Shackleton M
Ophthalmol Retina; 2024 Apr; 8(4):325-330. PubMed ID: 37852320
[TBL] [Abstract][Full Text] [Related]
31. Extrascleral Tumor Extension Associated with Localized Scleral Melt following Plaque Brachytherapy for Uveal Melanoma: Clinical and Histologic Findings.
Pham CM; Couch SM; Harocopos GJ
Ocul Oncol Pathol; 2018 Sep; 4(2):93-99. PubMed ID: 30320088
[TBL] [Abstract][Full Text] [Related]
32. High-Dose-Rate Yttrium-90 (
Finger PT
Ophthalmol Sci; 2024; 4(5):100513. PubMed ID: 38840779
[TBL] [Abstract][Full Text] [Related]
33. Patterns of care and survival outcomes after treatment for uveal melanoma in the post-coms era (2004-2013): a surveillance, epidemiology, and end results analysis.
Rao YJ; Sein J; Badiyan S; Schwarz JK; DeWees T; Grigsby P; Rao PK
J Contemp Brachytherapy; 2017 Oct; 9(5):453-465. PubMed ID: 29204166
[TBL] [Abstract][Full Text] [Related]
34. Regression of posterior uveal melanoma following iodine-125 plaque radiotherapy based on pre-treatment tumor apical height.
Miguel D; Saornil MA; de Frutos JM; García-Álvarez C; Alonso P; Diezhandino P
J Contemp Brachytherapy; 2021 Apr; 13(2):117-125. PubMed ID: 33897784
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of indigenously developed Ruthenium-106 eye plaque for brachytherapy of a spectrum of ocular tumors: A case series.
Kumar SV; Kumar A; Semwal MK; Mishra SK
J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S912-S916. PubMed ID: 38384078
[TBL] [Abstract][Full Text] [Related]
36. External Beam Radiotherapy in the Management of Uveal Melanoma.
Yilmaz MT; Sari SY; Zorlu F; Yazici G
Curr Treat Options Oncol; 2024 Jun; ():. PubMed ID: 38869695
[TBL] [Abstract][Full Text] [Related]
37. A study comparing baseline and best-corrected visual acuity after iodine-125 episcleral brachytherapy in uveal melanoma.
Miguel D; de Frutos JM; Alonso P; García-Álvarez C; Saornil MA; Diezhandino P; Garavis MI; Valencia P
J Contemp Brachytherapy; 2023 Oct; 15(5):350-356. PubMed ID: 38026075
[TBL] [Abstract][Full Text] [Related]
38. Trends in the Clinical Presentation of Uveal Melanoma During the COVID-19 Pandemic.
Adams OE; Tanke LB; Mundae R; Sodhi GS; Yu MD; Yonekawa Y; Dalvin LA; Tang PH
Ophthalmic Surg Lasers Imaging Retina; 2024 May; 55(5):278-284. PubMed ID: 38408223
[TBL] [Abstract][Full Text] [Related]
39. Treatment-Related Complications and Functional Results after Ruthenium-106 Brachytherapy in Small to Medium Size Uveal Melanomas (Part 2).
Lalos F; Flühs D; Guberina M; Bornfeld N; Stuschke M; Sauerwein W; Bechrakis NE
Klin Monbl Augenheilkd; 2024 Apr; ():. PubMed ID: 38395138
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of treatment for iris melanoma: surgical versus radiotherapeutic approaches.
Dockery PW; DeSimone JD; Liu CK; Achuck K; Hamburger J; Bas Z; Shields CL
Can J Ophthalmol; 2023 Nov; ():. PubMed ID: 38040029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
